SemBioSys to Present its New Joint Venture's Prospects to Investors at GCFF Vancouver Conference 2012

CALGARY, Feb. 3, 2012 /CNW/ - SemBioSy s Genetics Inc. (TSX:SBS) today announced the Company has been invi ted to participate in the GCFF Vancouver Conference 201 2 to be held tomorrow, February 4, 2012, at the Hilto n Vancouver Metrotown Hotel. SemBioSys management will be on hand to discuss the platform development collaboration agreement with Tasly Pharmaceutical Co., Ltd. of Tianjin, China, with investors.

The GCFF conference brings high-quality, exclusive financial information and knowledge to an audience of over 2,000 Chinese speaking investors in the Greater Vancouver Area, as well as over 50 public companies from North America and Greater China seeking a direct conversation with investors of Vancouver. The Vancouver chapter is one of the signature events that NAI Interactive of Vancouver and Shanghai has been organizing for over 13 years.

For more information on attending the conference, please visit:

Calgary, Alberta-based SemBioSys is a health and wellness company that utilizes its patented plant seed-based oilbody and genetic expression technology platforms to develop high-value proteins, oils, and drug candidates in oil seed plants. SemBioSys' seed-based protein and oil expression system can enable unique and novel products and exceptionally low cost of production with unprecedented scalability. SemBioSys is focusing the platform through global partnerships to develop healthy living, nutritional, and pharmaceutical products. SemBioSys is listed on the Toronto Stock Exchange under the ticker SBS. More information is available at

Forward Looking Statement and Disclaimer

This press release contains certain forward-looking statements, including, without limitation, statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and other similar expressions which constitute "forward-looking information" within the meaning of applicable securities laws. Forward-looking statements reflect the Company's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to: the fact that the Company is a development stage entity and currently relies on investment and not profits to fund it operations; the Company's ability to continue to secure and attract future strategic and investment capital; the Company's ability to continue to  successfully development its existing and future product candidates or commercialize them; the Company's exposure to changing global market dynamics, addressable markets and global regulatory environments required to register and market its product candidates; the acceptance of IND's by the FDA in respect of clinical studies; the submission of CTA's to the appropriate European authorities; the successful initiation and timely and successful completion of clinical studies; the establishment of future corporate alliances and partnership;, the impact of competitive products and pricing; new product development; uncertainties related to the regulatory approval process; and other risks detailed from time-to-time in the Company's ongoing filings with the Canadian securities regulatory authorities which filings can be found at On June 17, 2011, at our Annual and Special Meeting of Shareholders, shareholders unanimously approved a special resolution, approving an amendment to the Company's articles of incorporation to consolidate its issued and outstanding Common Shares. This provides the board of directors of the Company the authority, in its discretion, prior to June 17, 2012, to select the exact consolidation ration, provided that (i) the ration may be no smaller than one post-consolidation Share for every (8) pre-consolidation Common Shares and no larger than one post-consolidation Share for every thirty (30) pre-consolidation Common Shares, and (ii) the number of pre-consolidation Common Shares in the ratio must be a whole number of common shares. There is no current plan to effect such a Share Consolidation. However, if undertaken, the Company's total market capitalization immediately after the proposed consolidation may be lower than immediately before the proposed consolidation. A decline in the Common Shares after a Share Consolidation may result in a greater percentage decline than would occur in the absence of a consolidation, and the liquidity of the Common Shares could be adversely affected following such a consolidation. In addition, the consolidation may result in some shareholders owning "odd lots" of less than 100 Shares, on a post-consolidation basis, which may be difficult or more expensive to sell on a per share basis, than a round lot of shares. These are only some of the risks associated with a potential Share Consolidation. Further risks regarding the Company are set out in the annual information form found at Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable Canadian securities laws.

SOURCE SemBioSys Genetics Inc.

For further information:

SemBioSys Genetics Inc.
Rick Pierce
President, U.S. and International Operations
Phone: (617) 447-8299
        TMX Equicom
Ross Marshall
Senior Vice President
Phone: (416) 815-0700 ext. 238

Profil de l'entreprise

SemBioSys Genetics Inc.

Renseignements sur cet organisme


Jetez un coup d’œil sur nos forfaits personnalisés ou créez le vôtre selon vos besoins de communication particuliers.

Commencez dès aujourd'hui .


Remplissez un formulaire d'adhésion à CNW ou communiquez avec nous au 1-877-269-7890.


Demandez plus d'informations sur les produits et services de CNW ou communiquez avec nous au 1‑877-269-7890.